A "No-Formulas" Tour of Valuation
Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?" In this new white paper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Find out how valuation gets translated to deal terms and get a clear, conceptual framework for your drug's valuation.
About the Author:
Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com). Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. After doing licensing at what is now AstraZeneca, Dr. Pullan continued as head of oncology and hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company. For several years, she has been providing companies help in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical candidates to technologies, with both in- and out-licensing. She writes a free monthly newsletter Pullan's Pieces, with tidbits of science and business for about 3,600 readers. Interested readers may sign up by sending an email to firstname.lastname@example.org.